NEO · Neogenomics Inc

Track NEO — free Ask ALVIS about NEO

$15.28 +1.88 (+14.03%) At close · Jul 29

Market Cap

$1.99B

130.21M

Up next

Next earnings call

Oct 27, 2026 Est · unconfirmed · in 13 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 28, 2026

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Buy Momentum Strong Sentiment Bearish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.71

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +25%

above

Price vs 50-day avg +10%

above

RSI (14) 49

neutral

MACD trend Negative

52-week position 80%

mid-range

Momentum

relative strength

Strong

1-month return −6%

trailing

6-month return +7%

trailing

YTD return +14%

this year

Relative strength 0%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $12 › 200d $11 — 50d above 200d

Institutional flow Distributing

52 of 254 funds reported for Jun 30 · net -113.0K sh shares · +10 new

Insider flow Distributing

Net -$59.9K over 90 days · 100% sells

Short interest Rising

10.57% of float · ▲ +18.5% MoM · 6.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

254 holders — near 3-yr low, contrarian setup

Squeeze score 89

high risk · 0–100

Fundamentals

Weak

Revenue growth +10%

Y/Y

Gross margin 43%

contracting

EPS growth −300%

Y/Y

Free cash flow $-21.8M

Balance sheet $182.2M

net debt

Quant / Vol

risk profile

Very High

Volatility 62%

annualized · 1-yr

Max drawdown −46%

past year

ATR 5.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 28, 2026

Consolidated revenue · Updated FY 2026 Guidance Raised $802M – $806M

prior FY $727.33M midpoint +10.5% Y/Y

Net loss · Updated FY 2026 Guidance Initiated $-42M – $-34M

Adjusted EBITDA · Updated FY 2026 Guidance Raised $56M – $58M

Guided vs delivered · last 1 settled

Revenues full year 2025

guided $735M – $745M

guided $735M – $745M $727.33M Miss −1.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+25% Bullish

Price vs 50-day avg

+10% Bullish

RSI (14)

49 Neutral

MACD trend

Negative Bearish

52-week position

80% Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $12 › 200d $11 — 50d above 200d

Institutional flow Distributing

52 of 254 funds reported for Jun 30 · net -113.0K sh shares · +10 new

Insider flow Distributing

Net -$59.9K over 90 days · 100% sells

Short interest Rising

10.57% of float · ▲ +18.5% MoM · 6.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

254 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

52-wk low $5 Now $13 · 80% 52-wk high $16

vs 200-day avg +25% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$14M	second quarter of 2026	—

Adjusted Gross Profit Margin non-GAAP	48%	second quarter of 2026	—

Average revenue per clinical test	$515	second quarter of 2026	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NEO Neogenomics Inc this stock	$1.99B	+13.9%	+10.1%	—	10.6%
TMO Thermo Fisher Scientific Inc.	$214.21B	-0.4%	+0.4%	31.7	1.4%
DHR Danaher Corp /De/	$139.93B	-12.7%	+8.5%	35.3	1.4%
IDXX Idexx Laboratories Inc /De	$44.93B	-15.8%	+10.4%	41.9	2.7%
IQV Iqvia Holdings Inc.	$40.55B	+7.8%	+41.6%	30.2	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

259

% held: 97.8%
Reported: 52 of 254
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

249

View

Short & Settlement

Short Interest Rising

Shares short

13.8M

Days to cover: 6.0d
Change: +2.1M sh

View

Short Volume

Short vol %

62%

As of: Jul 29, 2026

Short Total

View

Fails to Deliver

FTD shares

15.1K

Value: $214.7K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

41.6%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$59.9K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: May 7, 2025

View

Financials

Net income (FY)

$-108.0M

EPS diluted: $-0.04

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 28, 2026
This year: 16

View

Proposed Sales

Value

$59.2K

Shares: 5.3K
Filed: Jun 15, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 28, 2026

View

Performance

	5D	20D	120D	MTD	YTD
NEO	-7.3%	-6.0%	+7.2%	-8.2%	+14.0%
SPY	-1.0%	0.0%	+7.4%	-0.8%	+8.6%
vs SPY	-6.3%	-5.9%	-0.2%	-7.4%	+5.3%

Key facts CIK 1077183 CUSIP 64049M209 13F (30d) 47 filings 47 filers Visit website Investor relations

NEO · Neogenomics Inc

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance